Annovis Bio Q1 net loss $0.63/sh; AD Phase 3 85% enrolled; NDA planned early 2027

Annovis Bio, Inc.

Net loss per share $0.63 (vs $0.32 in Q1 2025); R&D spend $16.7M (up from $5.0M).
Cash $14.2M at Mar 31, 2026; $10M April offering not included; 28.5M shares outstanding.
Phase 3 AD trial 85% enrolled, full enrollment on track summer 2026; DSMB safety recommendation positive.
PD OLE study 40% enrolled; NDA for buntanetap symptomatic AD treatment expected early 2027.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.